-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Info
On September 27, ChemoCentryx, Vifor Pharma, and Kissei Pharmaceutical jointly announced that the Ministry of Health, Labour and Welfare (MHLW) of Japan has approved the first-in-class oral small molecule complement C5a receptor inhibitor Tavneos (avacopan) to be marketed
ANCA-related vasculitis is a systemic disease.
Avacopan uses a novel and highly targeted mechanism of action in the treatment of ANCA-related vasculitis and other complement-driven autoimmune and inflammatory diseases
On July 6 this year, ChemoCentryx announced that the PDUFA target date for avacopan's new drug application in the United States has been extended to October 7, 2021